Scleroderma Newsroom
ISN News Manager: Jo Frowde
Media Stories
Scleroderma Archive
We maintain news archives for the most recent 3 years.
2019: Jan Feb Mar Apr May Jun Jul Aug Sep Oct Nov Dec
2021 - 2020 - 2019 - 2018

May 2019 Scleroderma News

Estradiol (E2) levels are elevated in older men with diffuse cutaneous SSc and are associated with decreased survival. Our study expands on previous work implicating E2 in dermal fibrosis in SSc and associates E2 levels with internal organ involvement and survival. PubMed, Arthritis Res Ther, 2019 Apr 2;21(1):85. (Also see Diffuse Scleroderma)

Increased monocyte count as a cellular biomarker for poor outcomes in fibrotic diseases: a retrospective, multicentre cohort study. Further investigation into the mechanistic role of monocytes in fibrosis might lead to insights that assist the development of new therapies. PubMed, Lancet Respir Med, 03/29/2019. (Also see Pulmonary Fibrosis)

Targeting of dermal myofibroblasts through death receptor 5 arrests fibrosis in mouse models of scleroderma. In vivo, TLY012 reverses established skin fibrosis to near–normal skin architecture in mouse models of scleroderma. PubMed, Nat Commun, 2019 Mar 8;10(1):1128. (Also see Fibroblasts)

Autoantibodies are present before the clinical diagnosis of systemic sclerosis (SSc). Our findings demonstrate that relevant seropositive autoantibodies often precede the clinical diagnosis of Ssc/no scleroderma renal crisis (SRC) and SSc/SRC. PubMed, PLoS One, 2019 Mar 26;14(3):e0214202. (Also see Antibodies)

Cannabinoid derivatives acting as dual PPAR?/CB2 agonists as therapeutic agents for systemic sclerosis (SSc). Altogether the results indicate that dual PPARγ/CB2 agonists qualify as a novel therapeutic approach for the treatment of SSc and other fibrotic diseases. PubMed, Biochem Pharmacol, 2019 Feb 27;163:321-334. (Also see Endocannabinoid System)

Phenotypes determined by cluster analysis and their survival in the prospective EUSTAR cohort of patients with systemic sclerosis (SSc). Our work suggests that restricting the subsets of SSc patients only to the cutaneous involvement may not capture the complete heterogeneity of the disease. PubMed, Arthritis Rheumatol, 04/10/2019. (Also see Cluster Studies)

Use of red cell distribution width (RDW) in a population at high risk for pulmonary hypertension (PH). The ease of obtaining RDW as a biomarker may help detect incident PH at earlier stages among patients who are at high risk for development of PH. PubMed, Respir Med, 2019 Apr;150:131-135. (Also see Pulmonary Hypertension Diagnosis)

Scleroderma renal crisis (SRC): risk factors for an increasingly rare organ complication. By far the highest risk for SRC was associated with the detection of anti-RNAP antibodies and proteinuria. PubMed, J Rheumatol, 04/01/2019. (Also see Kidney (Renal) Involvement)

Serum klotho concentrations inversely correlate with the severity of nailfold capillaroscopic patterns in patients with systemic sclerosis. In line with previous studies, our findings confirm that klotho plays a role in preventing microvascular damage detected with nailfold capillaroscopy. PubMed, Reumatismo, 2019 Apr 1;71(1):19-23. (Also see Nailfold Capillaroscopy)

Poor scleroderma-pulmonary hypertension-interstitial lung disease (SSc-PH-ILD) Prognosis May be Linked to Pulmonary Veno-occlusive Disease (PVOD). A high prevalence of PVOD SSc patients with pulmonary hypertension associated with interstitial lung disease may explain the poor prognosis observed in this patient group, according to a new study. Scleroderma News, 03/19/2019. (Also see Pulmonary Veno-Occlusive Disease)

Go to Scleroderma Medical News: April 2019

SCLERO.ORG is the world's leading nonprofit for trustworthy research, support, education and awareness for scleroderma and related illnesses. We are a 501(c)(3) U.S.-based public charitable foundation, established in 2002. Meet Our Team. Donations may also be mailed to:

International Scleroderma Network (ISN)
7455 France Ave So #266
Edina, MN 55435-4702 USA
Email [email protected]. Disclaimer. Privacy Policy.